Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Idebenone treatment in patients with OPA1-mutant dominant optic atrophy.

Brain : a journal of neurology - 1 Feb 2013

Barboni Piero, Valentino Maria Lucia, La Morgia Chiara, Carbonelli Michele, Savini Giacomo, De Negri Annamaria, Simonelli Francesca, Sadun Federico, Caporali Leonardo, Maresca Alessandra, Liguori Rocco, Baruzzi Agostino, Zeviani Massimo, Carelli Valerio

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to Follow-Up Studies
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Optic Atrophy, Autosomal Dominant

Share to Pilot Projects

Share to Treatment Outcome

Share to Ubiquinone

Share to Visual Acuity

Source

Identifiers

PMID: 23388408
DOI: 10.1093/brain/aws280

Genes

OPA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Idebenone treatment in patients with OPA1-mutant dominant optic atrophy.PMID 23388408Read ↗

Current treatment options for treating OPA1-mutant dominant optic atrophy.Semantic proximity Read ↗

A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.Semantic proximity Read ↗

Comparing EPI-743 treatment in siblings with Leber's hereditary optic neuropathy mt14484 mutation.Semantic proximity Read ↗

OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets.Semantic proximity Read ↗

Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial.Semantic proximity Read ↗

Leber’s hereditary optic neuropathy: Update on current diagnosis and treatmentSemantic proximity Read ↗

Targeting the OPA1 pathway in Autosomal Dominant Optic Atrophy (ADOA): 25 years from gene discovery to therapeutic strategy.Semantic proximity Read ↗

Dominant optic atrophy: novel OPA1 mutations and revised prevalence estimates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.